Skip to main
ABBV
ABBV logo

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 28%
Buy 42%
Hold 28%
Sell 0%
Strong Sell 3%

Bulls say

AbbVie is anticipated to achieve a high single-digit sales compound annual growth rate (CAGR) from 2024 to 2029, supported by robust expectations for its key products, particularly Skyrizi and Rinvoq. The revised sales forecast for Skyrizi now exceeds $20 billion and for Rinvoq surpasses $11 billion by 2027, indicating significant market demand and product performance. Despite some softening in the Aesthetics segment outlook, AbbVie's overall strong performance in immunology and enhancements in sales estimates highlight a positive trajectory for the company's financial growth.

Bears say

AbbVie's financial outlook is challenged by several factors, including disappointing commercial execution on key products such as Skyrizi, Rinvoq, and those in the aesthetics category, which are heavily reliant on discretionary spending. Furthermore, the company faces increased competitive pressure in its oncology portfolio and significant erosion of Humira’s market share due to the introduction of biosimilars, which is expected to intensify beyond 2025. Additionally, macroeconomic headwinds, including volatility in consumer spending and regulatory challenges, further complicate AbbVie's growth prospects, particularly in the aesthetics market, where recent sales have significantly underperformed expectations.

AbbVie (ABBV) has been analyzed by 36 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 42% recommend Buy, 28% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 36 analysts, AbbVie (ABBV) has a Buy consensus rating as of Aug 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $178.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $178.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.